sponsored
PatientsVille.com Logo

PatientsVille

Procrit Medical Research Studies

Up-to-date List of Procrit Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Procrit Medical Research Studies

Rank Status Study
1 Not yet recruiting PK and PD Parallel Study After Multiple Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant Epoetin and Eprex, in Healthy Subjects
Condition: Healthy
Intervention: Drug: Epoetin Alfa
Outcome Measures: rHuEPO Serum Concentration;   Plasma reticulocyte count
2 Not yet recruiting PK and PD Crossover Study After Single Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant Epoetin and Eprex, in Healthy Subjects.
Condition: Healthy
Intervention: Drug: Epoetin Alfa
Outcome Measures: rHuEPO serum concentration;   Plasma reticulocyte count
3 Not yet recruiting PK and PD Parallel Study After Multiple Dose, Intravenous Administration of Two Epoetin Alfa, Eritromax and Eprex, in Healthy Subjects.
Condition: Healthy
Intervention: Drug: Epoetin Alfa
Outcome Measures: rHuEPO serum concentration;   plasma reticulocyte count.
4 Not yet recruiting PK and PD Study After Single Dose, Intravenous Administration of Two Epoetin Alfa, Eritromax and Eprex, in Healthy Subjects
Condition: Healthy
Intervention: Drug: Epoetin Alfa
Outcome Measures: rHuEPO serum concentration;   plasma reticulocyte count
5 Recruiting Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Conditions: Anemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes
Interventions: Drug: lenalidomide;   Biological: epoetin alfa;   Other: laboratory biomarker analysis
Outcome Measures: MER defined as sustained transfusion independence in transfusion-dependent patients or a rise in hemoglobin > 2 g/dL in transfusion-independent patients with anemia for a minimum of 8 consecutive weeks;   Time to MER;   Duration of MER defined as the time interval between the documented date of MER and the earliest date of resumption of RBC transfusions > 2 units a reduction in hemoglobin concentration >= 2 g/dL in the absence of acute infection;   Rate of MER;   Minor erythroid response rate;   Cytogenetic response rate;   Bone marrow response (complete response and partial response) rate
6 Not yet recruiting Optimized Erythropoietin (EPO) Treatment
Condition: Neonatal Anemia
Interventions: Drug: Epoetin Alpha;   Drug: Biotinylated Red Blood Cells
Outcome Measures: Number of red blood cell transfusions;   Survival of Fetal Red Blood Cells in number of days
7 Unknown  Autoantibodies Against Human Recombinant Erythropoietin in Myelodysplatic Syndrome Patients
Condition: Myelodysplatic Syndrome
Intervention:
Outcome Measure: Correlate the Presence of Erythropoietin autoantibodies titer in MDS patients with an inadequate response (IR) to Human Recombinant Erythropoietin treatment
8 Unknown  Relationship Between Erythropoietin Administration and Stress Responses in Trauma Patients
Condition: Multiple Trauma
Interventions: Drug: erythropoietin;   Drug: placebo
Outcome Measures: apachi 2 saps 30 days mortality;   30 days mortality
9 Recruiting Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.
Condition: Adult Patients With Low- and Int-1-risk Myelodysplastic Syndrome.
Interventions: Drug: Erythropoietin alpha;   Drug: Deferasirox
Outcome Measures: Change in hemoglobin levels;   Change in hemoglobin, platelets and neutrophil levels;   Time to erythroid response;   Time to hematologic improvement;   Duration of erythroid response;   Number of adverse events (AEs) and serious adverse events (SAEs);   Iron parameters by change in serum ferritin
10 Not yet recruiting Erythropoietin Therapy for Children With Cerebral Palsy
Condition: Cerebral Palsy
Interventions: Drug: Erythropoietin;   Drug: Placebo erythropoietin
Outcome Measures: Changes in Quality of Movement;   Changes in Gross Motor Function;   Changes in Neurodevelopmental Outcomes;   Changes in Motor Development;   Changes in Spasticity
11 Recruiting Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEAT O)
Conditions: Hypoxic-ischemic Encephalopathy;   Neonatal Encephalopathy;   Birth Asphyxia
Interventions: Drug: Erythropoietin;   Drug: Normal saline
Outcome Measures: Markers of organ function;   Alberta Infant Motor Score (AIMS)
12 Not yet recruiting Effect of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in Subacute TBI
Condition: Traumatic Brain Injury
Intervention: Drug: Erythropoietin
Outcome Measures: Effect of 4 weeks of EPO administration on numbers of circulating EPCs in patients with persistent symptoms during the subacute period after TBI (within subject comparison).;   Comparison of the change of numbers of circulating EPC's between EPO and placebo groups.;   Effect of 4 weeks of EPO administration on plasma biomarkers of angiogenesis and inflammation, such as stem cell factor (SCF), vascular endothelial growth factor (VEGF), stromal-derived factor (SDF-1α); and matrix metalloproteinase-9 (MMP-9);   Effect of 4 weeks of placebo administration on numbers of circulating EPCs in patients with persistent symptoms during the subacute period after TBI.
13 Unknown  Intraocular Pharmacokinetics of Erythropoietin After Single Intravitreal Injection in Human
Conditions: Pharmacokinetics;   Erythropoietin
Intervention: Procedure: Vitrectomy
Outcome Measures: Concentration of erythropoietin in aqueous humor;   Concentration of erythropoietin in vitreous
14 Unknown  An Open-Label, Single-Arm Pilot Study of the Efficacy of Erythropoietin Alfa in Improving Peak Oxygen Consumption in Elderly Subjects With Unexplained Anemia
Condition: Anemia
Intervention: Drug: Epoetin alfa
Outcome Measures: Assess the ability of epoetin alfa to raise hemoglobin (Hb) levels in elderly community dwelling outpatients with unexplained anemia;   Assess the ability of epoetin alfa to improve physical function;   to assess the ability of epoetin alfa to improve cognitive function;   to assess the ability of epoetin alfa to improve quality of life;   Assess the safety of epoetin alfa in community dwelling outpatients with unexplained anemia
15 Not yet recruiting Treatment of Optic Neuritis With Erythropoietin
Condition: Optic Neuritis
Interventions: Drug: Erythropoietin;   Drug: Placebo
Outcome Measures: Retinal nerve fiber layer thickness;   Low contrast visual acuity;   Retinal nerve fiber layer thickness at the temporal sector of the optic nerve head;   Retinal nerve fiber layer thickness in the papillo-macular bundle;   Macular volume;   Visual acuity;   Contrast sensitivity;   Visual field;   Vision related quality of life;   Visually evoked potentials
16 Recruiting Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia
Condition: Antineoplastic Chemotherapy Induced Anemia
Intervention: Biological: Epoetin alfa
Outcome Measures: Number of subjects with adverse events and percentage of therapy withdrawals due to treatment emergent adverse events;   Hemoglobin levels and percentage of responders;   Quality of life;   Hemoglobin levels ≥ 2 g/dl
17 Recruiting Neuroprotective Role of Erythropoietin in Perinatal Asphyxia
Condition: Perinatal Asphyxia
Intervention: Drug: Erythropoietin
Outcome Measures: Death and or disability at 12-18 months of life;   Gross motor delay
18 Unknown  The Effect of Erythropoietin Usage in Renal Function After Kidney Transplantation, in Early Phase, in Contrast to Placebo Group
Condition: Transplantation, Kidney
Interventions: Drug: Erythropoietin;   Drug: Placebo
Outcome Measure: We will study the well-being of renal function by evaluation of plasma Cr,GFR,PTDA scan & biopsy proven(If it is necessary to prove the rejection)about measuring of patient - graft survival.
19 Recruiting Efficacy of Erythropoietin to Improve Survival and Neurological Outcome in Hypoxic Ischemic Encephalopathy
Condition: Hypoxic Ischemic Encephalopathy
Interventions: Drug: erythropoietin Beta;   Drug: Placebo
Outcome Measures: Survival without neurologic sequelea;   Mortality rates;   Rate of moderate and severe sequelae;   Aspect of brain lesions on MRI;   Tolerance of treatment
20 Unknown  The Effect of Recombinant Human Erythropoietin (rHuEPO) on Microcircualtory Alteration in Intensive Care Unit Patients With Severe Sepsis and Septic Shock
Conditions: Sepsis;   Shock
Intervention:
Outcome Measure:

These studies may lead to new treatments and are adding insight into Procrit etiology and treatment.

A major focus of Procrit research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Procrit